is taking over Epidauros Biotechnologie in a cash transaction valued at EUR 8.75 million, or approximately $11.87 million. The transaction will boost the company’s biomarker development efforts and pharmacogenomics services.
“Epidauros’ intellectual property portfolio holds great promise in critical areas related to drug transport and distribution,” according to Drew Fromkin, Clinical Data’s president and CEO. “In turn, these genetic markers should play a significant role in better understanding drug response in individuals.”
Epidauros’ portfolio includes biomarkers in genes relating to prominent drug transporters such as MDR1, OCT, and MRP1, and cytochrome P450 drug metabolizing genes such as CYP2B6 and CYP2D6.
“Genes for drug transporters, such as MDR1 and OCT1, will prove to be as important as the cytochrome P450 system in determining plasma and tissue levels of drugs, and thereby the efficacy and toxicity of drugs in disease areas including but not limited to oncology, cardiology, CNS, metabolic and inflammatory diseases, and pain,” states Munir Pirmohamed, professor of clinical pharmacology at The University of Liverpool, who has collaborated with Epidauros.
Additionally, Fromkin notes that besides the biomarker portfolio, Clinical Data will also gain access to laboratories. “We expect the capabilities of Epidauros’ laboratories to complement those of Clinical Data and to contribute a strong local presence in the important German market. With our operations in the U.K. and France, this transaction provides Clinical Data with laboratories in three top European markets.”